Evidence map›Paper›PMID 34972700›Full record

ArticleIn vivo (Athens, Greece)

Fluorescent Anti-MUC5AC Brightly Targets Pancreatic Cancer in a Patient-derived Orthotopic Xenograft.

Michael A Turner, Hannah M Hollandsworth, Hiroto Nishino, Siamak Amirfakhri, Thinzar M Lwin, Andrew M Lowy, Sukhwinder Kaur, Gopalakrishnan Natarajan, Kavita Mallya, Robert M Hoffman and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Specific Targeting and Labeling of Colonic Polyps inCurrent issues in molecular biology · 2023
    Article
  9. Review
  10. Antibody-Based Approaches to Target Pancreatic Tumours.Antibodies (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Michael A TurnerDepartment of Surgery, University of California San Diego, La Jolla, CA, U.S.A.
Hannah M HollandsworthDepartment of Surgery, University of California San Diego, La Jolla, CA, U.S.A.
Hiroto NishinoDepartment of Surgery, University of California San Diego, La Jolla, CA, U.S.A.
Siamak AmirfakhriDepartment of Surgery, University of California San Diego, La Jolla, CA, U.S.A.
Thinzar M LwinDepartment of Surgery, University of California San Diego, La Jolla, CA, U.S.A.
Andrew M LowyDepartment of Surgery, University of California San Diego, La Jolla, CA, U.S.A.
Sukhwinder KaurDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, U.S.A.
Gopalakrishnan NatarajanDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, U.S.A.
Kavita MallyaDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, U.S.A.
Robert M HoffmanDepartment of Surgery, University of California San Diego, La Jolla, CA, U.S.A.
Surinder K BatraDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, U.S.A.
Michael BouvetDepartment of Surgery, University of California San Diego, La Jolla, CA, U.S.A.; mbouvet@ucsd.edu.
University of California San Diego · USUniversity of Nebraska Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOverexpression of mucin-5AC (MUC5AC) makes it a targetable biomarker in pancreatic cancer. The present study evaluated tumor targeting with a MUC5AC antibody conjugated to a near-infrared dye in a patient-derived orthotopic xenograft (PDOX) mouse model. MATERIALS AND

methodsMUC5AC monoclonal antibody was conjugated to the near-infrared dye IRDye800CW to synthesize MUC5AC-IR800. PDOX models were established by implanting a high-MUC5AC-expressing patient-derived pancreatic tumor on the pancreas of nude mice. After 4 weeks of PDOX tumor growth, mice were imaged after receiving MUC5AC-IR800 (75 μg) intravenously.

resultsIn the PDOX models, MUC5AC-IR800 selectively and brightly targeted the pancreatic tumor (tumor to background ratio: 2.46±0.465).

conclusionMUC5AC-IR800 provides distinct visualization of pancreatic tumors. MUC5AC-IR800 may be used clinically in the future to improve pancreatic cancer resection. This novel fluorescent probe is also promising for targeting of pre-malignant pancreatic lesions with subsequent resection under fluorescence guidance.

Indexed as

Pancreatic NeoplasmsAnimalsFluorescent DyesHeterograftsHumansMiceMice, NudeXenograft Model Antitumor AssaysFluorescent Dyesantibodyfluorescence guided surgeryMUC5ACmucinPancreatic cancerPDOXtumor-specific imaging

Identifiers

PMID34972700
PMCPMC8765132
OpenAlexW4205519530

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.